A retrospective study to assess the risk of bladder cancer in type-2 diabetic patients treated with pioglitazone
Introduction: Pioglitazone has been a cornerstone of oral hypoglycemic therapy. Concerns have been raised about its association with urinary bladder cancer. Considering the wide usage of this drug, concrete and multiple population-based studies are needed to establish the safety of this drug. The pr...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2021-01-01
|
| Series: | Perspectives in Clinical Research |
| Subjects: | |
| Online Access: | http://www.picronline.org/article.asp?issn=2229-3485;year=2021;volume=12;issue=1;spage=9;epage=13;aulast= |
| _version_ | 1818954735623864320 |
|---|---|
| author | Prabhat Agrawal Apoorva Jain Ashish Gautam Ashwini Kumar Nigam Nikhil Pursnani Maaz Farooqui |
| author_facet | Prabhat Agrawal Apoorva Jain Ashish Gautam Ashwini Kumar Nigam Nikhil Pursnani Maaz Farooqui |
| author_sort | Prabhat Agrawal |
| collection | DOAJ |
| description | Introduction: Pioglitazone has been a cornerstone of oral hypoglycemic therapy. Concerns have been raised about its association with urinary bladder cancer. Considering the wide usage of this drug, concrete and multiple population-based studies are needed to establish the safety of this drug. The present retrospective study is aimed to assess the association of pioglitazone with urinary bladder cancer.
Materials and Methods: Clinical records of 4170 patients (2085 pioglitazone users and similar number of nonpioglitazone users) attending the diabetes clinic at a tertiary level teaching hospital were accessed, and the patients were subjected to symptom-directed questionnaire, urine examination, and cystoscopy and bladder biopsy (whenever clinically indicated). The risk of bladder cancer was also assessed with respect to cumulative dose and duration of pioglitazone.
Results: We did not observe any increased risk of bladder malignancy with pioglitazone exposure; furthermore, there was no association with cumulative dose and duration of pioglitazone therapy. Pioglitazone was found to be effective and safe in managing glycemic control in diabetic patients. |
| first_indexed | 2024-12-20T10:26:54Z |
| format | Article |
| id | doaj.art-c7e0ae52cc4d4b839b9a90d2adfcab86 |
| institution | Directory Open Access Journal |
| issn | 2229-3485 |
| language | English |
| last_indexed | 2024-12-20T10:26:54Z |
| publishDate | 2021-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Perspectives in Clinical Research |
| spelling | doaj.art-c7e0ae52cc4d4b839b9a90d2adfcab862022-12-21T19:43:49ZengWolters Kluwer Medknow PublicationsPerspectives in Clinical Research2229-34852021-01-0112191310.4103/picr.PICR_192_18A retrospective study to assess the risk of bladder cancer in type-2 diabetic patients treated with pioglitazonePrabhat AgrawalApoorva JainAshish GautamAshwini Kumar NigamNikhil PursnaniMaaz FarooquiIntroduction: Pioglitazone has been a cornerstone of oral hypoglycemic therapy. Concerns have been raised about its association with urinary bladder cancer. Considering the wide usage of this drug, concrete and multiple population-based studies are needed to establish the safety of this drug. The present retrospective study is aimed to assess the association of pioglitazone with urinary bladder cancer. Materials and Methods: Clinical records of 4170 patients (2085 pioglitazone users and similar number of nonpioglitazone users) attending the diabetes clinic at a tertiary level teaching hospital were accessed, and the patients were subjected to symptom-directed questionnaire, urine examination, and cystoscopy and bladder biopsy (whenever clinically indicated). The risk of bladder cancer was also assessed with respect to cumulative dose and duration of pioglitazone. Results: We did not observe any increased risk of bladder malignancy with pioglitazone exposure; furthermore, there was no association with cumulative dose and duration of pioglitazone therapy. Pioglitazone was found to be effective and safe in managing glycemic control in diabetic patients.http://www.picronline.org/article.asp?issn=2229-3485;year=2021;volume=12;issue=1;spage=9;epage=13;aulast=adverse drug reactiondiabetesoral hypoglycemicpioglitazoneurinary bladder cancer |
| spellingShingle | Prabhat Agrawal Apoorva Jain Ashish Gautam Ashwini Kumar Nigam Nikhil Pursnani Maaz Farooqui A retrospective study to assess the risk of bladder cancer in type-2 diabetic patients treated with pioglitazone Perspectives in Clinical Research adverse drug reaction diabetes oral hypoglycemic pioglitazone urinary bladder cancer |
| title | A retrospective study to assess the risk of bladder cancer in type-2 diabetic patients treated with pioglitazone |
| title_full | A retrospective study to assess the risk of bladder cancer in type-2 diabetic patients treated with pioglitazone |
| title_fullStr | A retrospective study to assess the risk of bladder cancer in type-2 diabetic patients treated with pioglitazone |
| title_full_unstemmed | A retrospective study to assess the risk of bladder cancer in type-2 diabetic patients treated with pioglitazone |
| title_short | A retrospective study to assess the risk of bladder cancer in type-2 diabetic patients treated with pioglitazone |
| title_sort | retrospective study to assess the risk of bladder cancer in type 2 diabetic patients treated with pioglitazone |
| topic | adverse drug reaction diabetes oral hypoglycemic pioglitazone urinary bladder cancer |
| url | http://www.picronline.org/article.asp?issn=2229-3485;year=2021;volume=12;issue=1;spage=9;epage=13;aulast= |
| work_keys_str_mv | AT prabhatagrawal aretrospectivestudytoassesstheriskofbladdercancerintype2diabeticpatientstreatedwithpioglitazone AT apoorvajain aretrospectivestudytoassesstheriskofbladdercancerintype2diabeticpatientstreatedwithpioglitazone AT ashishgautam aretrospectivestudytoassesstheriskofbladdercancerintype2diabeticpatientstreatedwithpioglitazone AT ashwinikumarnigam aretrospectivestudytoassesstheriskofbladdercancerintype2diabeticpatientstreatedwithpioglitazone AT nikhilpursnani aretrospectivestudytoassesstheriskofbladdercancerintype2diabeticpatientstreatedwithpioglitazone AT maazfarooqui aretrospectivestudytoassesstheriskofbladdercancerintype2diabeticpatientstreatedwithpioglitazone AT prabhatagrawal retrospectivestudytoassesstheriskofbladdercancerintype2diabeticpatientstreatedwithpioglitazone AT apoorvajain retrospectivestudytoassesstheriskofbladdercancerintype2diabeticpatientstreatedwithpioglitazone AT ashishgautam retrospectivestudytoassesstheriskofbladdercancerintype2diabeticpatientstreatedwithpioglitazone AT ashwinikumarnigam retrospectivestudytoassesstheriskofbladdercancerintype2diabeticpatientstreatedwithpioglitazone AT nikhilpursnani retrospectivestudytoassesstheriskofbladdercancerintype2diabeticpatientstreatedwithpioglitazone AT maazfarooqui retrospectivestudytoassesstheriskofbladdercancerintype2diabeticpatientstreatedwithpioglitazone |